To include your compound in the COVID-19 Resource Center, submit it here.

Alexion's long-acting C5 inhibitor meets in Phase III

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said that ALXN1210, its long-acting formulation of Soliris eculizumab, met the co-primary and four key secondary endpoints in the Phase III ALXN1210-PNH-301 trial to treat paroxysmal nocturnal hemoglobinuria (PNH). The company reiterated its plans to submit regulatory applications

Read the full 424 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE